Skip to main content
Premium Trial:

Request an Annual Quote

MetriGenix, Temple University to Build Protein Chips for Heart Disease

NEW YORK, April 3 - MetriGenix and Temple University plan to develop protein chips that target cardiovascular disease, the company said today.

Under the terms of the collaboration, Temple scientists will provide MetriGenix with a selection of proteins linked to congestive heart failure culled from in-house research and general literature. MetriGenix, in turn, will use its 4D assay system to produce flow-thru biochips with antibodies to monitor these proteins. 

The agreement also calls for researchers at Temple to use the 4D system to screen some 350 archived human myocardial tissue samples with an expanded molecular target set. This part of the deal got some financial help from the National Institute of Aging, according to MetriGenix.

Financial terms of the agreement were not disclosed.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.